Clinical trials: Platelet Aggregation Inhibitors, active
Peripheral Arterial Disease (PAD), Amputation
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore…
- Conditions
- Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- NCT07613840
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 484 people
- Sponsor
- Massachusetts General Hospital
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications.
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
- Trial name
- TALISCHER-SAH (NCT07821008)
- Testing
- Experimental group: ticagrelor
- Where
- 7 sites in France
- Volunteers
- 274 people
- Sponsor
- University Hospital, Toulouse
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Atrial Fibrillation, Atrial Appendage
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Atrial Appendage, Anticoagulants, Stroke
- Trial name
- APPENDAGE (NCT04796714)
- Testing
- Double antiplatelet therapy, Aspirin, Brain MRI
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 872 sites in United States, Australia and 45 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Antiplatelet Agents, Perioperative Care
Optimal PERioperative Antiplatelet Therapy Investigation ON Abdominal Surgery After Coronary Stent Implantation
The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.
- Trial name
- OPERATION (NCT06723145)
- Testing
- Aspirin, Aspirin interruption
- Where
- Japan
- Volunteers
- 1,200 people
- Sponsor
- Kyoto University
Antiplatelet Drug, Acute Coronary Syndrome
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel coated to the balloon.
- Conditions
- Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon
- Trial name
- CAGEFREEII (NCT04971356)
- Testing
- Aspirin 100mg for 1-month (immediately after PCI), Ticagrelor 90mg for 6-month (immediately after PCI), Aspirin 100mg for 6-month (6-month post PCI)
- Where
- China
- Volunteers
- 1,948 people
- Sponsor
- Xijing Hospital
Ischemic Stroke
Transmission Electron Microscopy Images for Platelet Ultrastructural Criteria Before and After the Onset of an Antiplatelet Agent
The aim of the pilot study is to collect all the ultrastructural platelet characteristics by transmission electron microscopy before and after the onset of an antiplatelet treatment in patients hospitalized for an ischemic stroke…
- Trial name
- ELECTROSTROKE (NCT05004233)
- Testing
- Blood collection before antiplatelet treatment, Blood collection after antiplatelet treatment
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Head Injury Trauma, Emergencies
Platelet Inhibitor Treated Patients With Head Injury Trauma Meeting NICE Criteria : is the CT-scan Mandatory ?
At the emergencies rooms, patients with head trauma meeting one of the NICE criteria, which include antiplatelet inhibitors treatment, are considered as patients with a risk of cerebral haemorrage and are taken systematically for…
- Trial name
- TCAP (NCT03687528)
- Testing
- CT-scanner
- Where
- 12 sites in France
- Volunteers
- 3,200 people
- Sponsor
- Rennes University Hospital
Von Willebrand Diseases, Major Constitutional Thrombopathy
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow…
- Conditions
- Von Willebrand Diseases, Major Constitutional Thrombopathy, Patient on Antiplatelet Drugs
- Trial name
- INDONESIA (NCT03773159)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation.
- Conditions
- Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease
- Trial name
- TAILOR-DAPT (NCT05732701)
- Testing
- Algorithm-guided DAPT duration, Standard-of-care DAPT duration
- Where
- 4 sites in Bosnia and Herzegovina, Italy and 1 more
- Volunteers
- 2,788 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
ACS - Acute Coronary Syndrome, Ticagrelor
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to…
- Conditions
- ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
- Trial name
- FLORA-ACS (NCT07203846)
- Testing
- Rifaximin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Acute Non-variceal Upper Gastrointestinal Hemorrhage, Coronary Heart Disease
Timing of Endoscopy in Coronary Heart Disease Patients Taking Antiplatelet Drugs With Acute Non-variceal Upper Gastrointestinal Bleeding
This is a prospective randomized controlled trial (RCT) evaluating the optimal timing of endoscopy in patients with coronary heart disease who are taking antiplatelet drugs and present with acute non-variceal upper…
- Trial name
- PACT-UGIB (NCT07507162)
- Testing
- Urgent Endoscopy (Within 12 Hours of Admission), Early Endoscopy (12-24 Hours After Admission)
- Volunteers
- 212 people
- Sponsor
- Beijing Anzhen Hospital
Platelet Thrombus
Characterization of Exosomes Platelets-released
Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics.
- Trial name
- EXOPLT (NCT06298682)
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Centro Cardiologico Monzino
Coronary Artery Disease, Antiplatelet Drugs
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and…
- Trial name
- OPTION2 (NCT06451198)
- Testing
- Indobufen, Aspirin, Ticagrelor
- Where
- China
- Volunteers
- 2,846 people
- Sponsor
- Shanghai Zhongshan Hospital
Chronic Coronary Syndrome
Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2
A prospective, multi-center, open-label, randomized controlled, and superiority trial. The trial will compare clinical outcomes between discontinuation of antiplatelet agent and continuation of antiplatelet agent in HBR patients…
- Trial name
- DCB-HBR-2 (NCT06742931)
- Testing
- Discontinuation of antiplatelet agent group, Continuation of antiplatelet agent group
- Where
- 18 sites in South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Gastrointestinal Bleeding, Antiplatelet Therapy
MCE Identifying Bleeding Lesions in Patients with Antiplatelet Drugs-Related Acute Non-Hematochezia Gastrointestinal Bleeding
The goal of this clinical trial is to explore the diagnostic efficacy of detachable string magnetically controlled capsule endoscopy (ds-MCE) for identification of bleeding lesions in patients with antiplatelet drugs-related…
- Trial name
- MCE (NCT06698874)
- Testing
- ds-MCE and EGD examinations
- Where
- 4 sites in China
- Volunteers
- 204 people
- Sponsor
- Changhai Hospital
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Platelet Aggregation, Type 2 Diabetes
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period.
- Conditions
- Platelet Aggregation, Type 2 Diabetes, Aspirin, Diabetes Mellitus, Type 2
- Trial name
- APPEASEDII (NCT05702463)
- Testing
- Aspirin 81Mg Ec Tab twice daily for 7 days, Aspirin 40Mg Chew Tab twice daily for 7 days, Aspirin 162 mg EC Tab once daily for 7 days
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Montreal Heart Institute